BioMarin Pharmaceutical Income Statement Analysis

Revenue, earnings, and profit margins in billions USD

Scroll to see more
BioMarin Pharmaceutical Inc. income statement - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue2.852.422.101.851.861.701.49
Cost of Revenue0.580.530.500.470.520.360.32
Gross Profit2.271.891.591.381.341.341.18
Operating Expenses
Research & Development0.750.750.650.630.630.720.70
Selling, General & Administrative0.910.890.820.760.740.680.60
Operating Expenses1.701.701.541.451.361.751.33
Operating Income0.570.190.06-0.07-0.04-0.10-0.16
Other Income/Expense
Interest Income0.070.060.020.010.020.000.02
Interest Expense-0.010.010.010.01-0.030.000.04
Other Income/Expense0.00-0.040.090.00-0.06-0.020.03
Income
Income Before Tax0.540.190.15-0.08-0.04-0.09-0.14
Income Tax Expense0.110.020.01-0.01-0.90-0.07-0.07
Net Income0.430.170.14-0.060.85-0.02-0.08
Net Income - Continuous Operations0.430.170.14-0.060.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA0.670.310.270.050.080.050.00
EBIT0.570.200.16-0.06-0.02-0.07-0.10
Depreciation & Amortization0.100.060.060.060.040.090.03
Earnings Per Share
Basic EPS2.001.001.00-5.00--
Diluted EPS2.001.001.00-5.00--
Basic Shares Outstanding0.190.190.190.180.180.180.18
Diluted Shares Outstanding0.200.190.190.180.190.180.18